COPD trials recruiting in Arizona

All COPD trials nationally

Cities in Arizona

Recruiting trials in Arizona

• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
  NCT06283966 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · Arizona: Gilbert, Glendale, Mesa, Phoenix
• A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
  NCT07082738 · Phase: Phase 2 · Ages: 40 Years and older · Sex: All (male and female) · Arizona: Glendale, Phoenix
• A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
  NCT06883305 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · Arizona: Phoenix, Tucson
• A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
  NCT06878261 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · Arizona: Phoenix, Scottsdale
• A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
  NCT07363694 · Phase: Phase 2, Phase 3 · Ages: 35 Years to 80 Years · Sex: All (male and female) · Arizona: Chandler, Phoenix
• An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema
  NCT06035120 · Phase: Not applicable (e.g. observational or device study) · Ages: 40 Years to 80 Years · Sex: All (male and female) · Arizona: Phoenix
• Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3
  NCT06891755 · Phase: Not applicable (e.g. observational or device study) · Ages: 40 Years to 84 Years · Sex: All (male and female) · Arizona: Gilbert
• Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
  NCT07059091 · Phase: Phase 2 · Ages: 40 Years and older · Sex: All (male and female) · Arizona: Tucson
• Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
  NCT07190209 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · Arizona: Chandler, Phoenix, Surprise
• Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
  NCT07190222 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · Arizona: Tucson
• Pulmonary Rehabilitation for Rural Patients With COPD
  NCT06847061 · Phase: Not applicable (e.g. observational or device study) · Ages: 40 Years and older · Sex: All (male and female) · Arizona: Scottsdale
• SPIROMICS Study of Early COPD Progression (SOURCE)
  NCT05033990 · Phase: Not specified · Ages: 30 Years to 55 Years · Sex: All (male and female) · Arizona: Scottsdale
• STRIVE Post-Market Registry Study
  NCT04302272 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Phoenix
• To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
  NCT07684820 · Phase: Phase 2 · Ages: 40 Years to 85 Years · Sex: All (male and female) · Arizona: Phoenix
• Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD
  NCT07610395 · Phase: Phase 2 · Ages: 40 Years to 85 Years · Sex: All (male and female) · Arizona: Tempe
• myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home
  NCT05204888 · Phase: Not applicable (e.g. observational or device study) · Ages: 30 Years and older · Sex: All (male and female) · Arizona: Scottsdale